The central surprise of the study lies in the asymmetry of this crosstalk. When the team exposed human monocytes and macrophages to TNF and IL-4 together, they expected the classic pattern of mutual cross-inhibition that has dominated the literature on antagonistic cytokine pairs. What they observed instead was cooperation. TNF functioned predominantly as a partner that expanded and intensified the set of genes switched on by IL-4, rather than as a brake. The interleukin’s own signature was not blunted by the presence of the inflammatory signal; it was broadened by it. This finding suggests that the anti-inflammatory cytokine does not merely survive contact with its proinflammatory counterpart but actively exploits TNF signaling to shape the scope of its own transcriptional output.

The selectivity of the reverse direction is equally striking. IL-4 did not shut down TNF signaling wholesale. Instead, it targeted a specific component of the TNF-induced program: the interferon response. Genes driven by interferon regulatory pathways, which form an important antimicrobial and immune-activating arm of TNF signaling, were selectively inhibited by IL-4. The broader inflammatory gene expression elicited by TNF, however, remained largely intact. In other words, IL-4 pruned the interferon branch of the TNF response while leaving the rest of the inflammatory tree standing. This level of precision implies that the two cytokines negotiate at the level of individual gene programs rather than through a simple global on-off switch.

Among the genes that responded synergistically to the combined cytokines were sets with well-recognized roles in regulating inflammation and promoting tissue repair. When TNF and IL-4 were present together, these gene sets were induced to levels far exceeding what either cytokine achieved alone. The synergy was not a minor quantitative effect confined to a handful of transcripts; it encompassed coordinated gene programs that shape how macrophages behave in damaged tissue. Because macrophages are central orchestrators of the transition from inflammation to repair, the identity of the genes governed by this combined signal carries weight for understanding how wounds progress from the inflammatory phase to the rebuilding phase.

To test whether this laboratory-scale crosstalk mattered in a living tissue context, the investigators turned to a skin wound-healing model. Their analysis revealed that the synergistically induced gene sets were highly expressed during precisely the phase of wound repair when TNF and IL-4 are co-expressed in the healing tissue. This temporal overlap is biologically meaningful. It suggests that the cooperative program observed in cultured human monocytes is not an artifact of the dish but reflects a naturally occurring transcriptional state in which the two cytokines act together in time and space. During the window when inflammation and repair must be balanced, the combined TNF and IL-4 signal appears to help define the macrophage phenotype that supports that balance.

Mechanistically, the study traced the crosstalk to epigenetic chromatin-mediated mechanisms rather than to changes in signaling alone. Transcription factors are the proteins that bind DNA and switch genes on, but whether they can reach their targets depends on the state of the chromatin, the packaged form of DNA in the cell. The researchers found that cooperation between NF-κB, the canonical transcription factor activated by TNF, and STAT6, the transcription factor activated downstream of the IL-4 receptor, underpinned the synergistic gene expression. Rather than acting through separate gene sets, these two pathways converged on shared regulatory elements, allowing a proinflammatory signal and an anti-inflammatory signal to jointly open and activate the same loci.

A second epigenetic mechanism involved the erasure of a repressive histone mark. Histone H3 lysine 27 trimethylation, abbreviated H3K27me3, is a chemical modification of chromatin that is generally associated with silenced or po genes held in a inactive state. In the presence of the combined cytokine signal, this negative mark was removed from relevant genomic regions, lifting a layer of repression and permitting transcriptional activation. The removal of H3K27me3 provides a plausible explanation for how the synergy produces gene induction that neither cytokine can accomplish alone: TNF signaling through NF-κB helps remodel the chromatin landscape in a way that makes IL-4-driven, STAT6-dependent transcription possible at genes that would otherwise remain closed.

The third mechanistic pillar was the selective inhibition of IRF1, a transcription factor that mediates interferon responses and contributes to the interferon arm of TNF signaling. By suppressing IRF1, IL-4 was able to disassemble the interferon component of the TNF program without dismantling TNF-driven inflammatory gene expression more broadly. This selective targeting helps explain the otherwise paradoxical combination of results: cooperation at repair-related and inflammation-regulating genes on one hand, and selective antagonism at interferon-responsive genes on the other. The crosstalk is therefore not a single mechanism but a coordinated set of chromatin-level events that produce different outcomes at different classes of target genes.

The authors frame these results as identifying a mechanism for the expansion of the IL-4 response, and the implications extend beyond basic cytokine biology. If TNF signaling is required for the full breadth of the IL-4 program in monocytes and macrophages, then broadly suppressing TNF, as many anti-TNF therapies do in conditions such as rheumatoid arthritis and inflammatory bowel disease, may have consequences that reach into the tissue-repair arm of immunity, not only the inflammatory arm. The study also highlights the complexity of crosstalk between antagonistic cytokines more generally, showing that pairs of signals long assumed to cancel each other out can instead cooperate on select gene responses that are important for immune function and tissue repair. Cross-inhibition, the traditional focus of the field, turns out to be only part of the story.

As with any study, the findings come with scope conditions worth keeping in view. The human cell work was performed in primary monocytes and macrophages, and the in vivo evidence comes from a skin wound-healing model, so extending the conclusions to other tissues, other disease settings, and other cytokine combinations will require further investigation. Nevertheless, the work offers a concrete and testable framework: antagonistic cytokines negotiate through transcription factor cooperation, targeted histone modification, and selective inhibition of intermediary factors such as IRF1. For a field that has long organized itself around the idea that inflammatory and anti-inflammatory signals are opponents, the demonstration that TNF can serve as a costimulator of the IL-4 program, and that the two jointly govern genes central to repair, is a reminder that the immune system’s wiring is built less on simple opposition than on context-dependent partnership.

Subject of Research: Crosstalk between the cytokines TNF and IL-4 in regulating gene expression in human monocytes and macrophages

Article Title: IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages

Article References: Yuan, R., Yang, C., Mishra, B., Oliver, D., Bell, R. D., & Ivashkiv, L. B. (2026). IL-4 exploits TNF signaling to shape its gene expression signature in monocytes and macrophages. Nature Communications. https://doi.org/10.1038/s41467-026-78528-3

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78528-3

Keywords: IL-4, TNF, monocytes, macrophages, cytokine crosstalk, NF-kB, STAT6, H3K27me3, IRF1, gene expression, wound healing, immunology

The research team, led by Su-Hyeon Lee and Deok-Gie Kim, with corresponding authors Byungjin Hwang and Dong Jin Joo, took an unusually rigorous approach to a difficult clinical problem. They recruited 20 liver transplant recipients and collected paired samples of peripheral blood mononuclear cells, the circulating immune cells that include lymphocytes and monocytes, both before surgery and after transplantation. Ten of these patients went on to develop acute rejection and ten did not. Crucially, the two groups were matched for a battery of clinical variables that could otherwise confound the analysis, including age, sex, hepatocellular carcinoma status, autoimmune disease status, ABO blood group compatibility, and donor age. By controlling for these factors, the investigators could be more confident that the immunological differences they found were genuinely linked to rejection rather than to incidental patient characteristics.

Technically, the study is a tour de force of single-cell multi-omics. Rather than averaging gene expression across bulk tissue, the team used single-cell RNA sequencing to profile 88,940 high-quality individual cells, preserving the identity and state of each immune cell. They paired this transcriptomic readout with T cell receptor sequencing, which reads the unique genetic rearrangements that give each T cell its antigen-specific receptor. This combination allowed them to track not only which cell types were present and what genes they were expressing, but also how T cell clones expanded, contracted, and diversified over time. On top of the sequencing data, the researchers layered computational analyses of gene regulatory networks and intercellular communication, reconstructing the signaling conversations between immune cell populations that precede and accompany rejection.

The most striking finding is that the immune systems of future rejecters looked different before transplantation. Patients who later developed acute rejection already showed a distinct pre-transplant immune state compared with those who tolerated their new livers. Natural killer cells in the rejection group displayed an inflammatory activation profile with enhanced responsiveness to interferon, a family of signaling proteins central to antiviral and immune defense responses. Monocytes, the innate immune cells that patrol the blood and seed tissues, showed altered composition and transcriptional programs dominated by interferon-associated signatures. Together, these observations suggest a systemic, low-grade inflammatory readiness in the circulation of patients whose immune systems would later turn against the graft.

The adaptive immune side of the story was equally revealing. Before surgery, recipients who went on to reject showed a skewing of their CD8 T cell compartment toward effector memory states. Effector memory CD8 T cells are the rapid-response soldiers of the immune system: they circulate in the blood and peripheral tissues, and when they encounter their target antigen they can immediately deploy cytotoxic machinery without the delay required for naive T cells to differentiate. A pre-existing bias toward this compartment means the patient carries a standing army of cytotoxic cells primed for fast action, a configuration that could plausibly accelerate an attack on donor tissue once transplantation delivers a flood of foreign antigens.

After transplantation, the divergence between the two groups did not close; it widened in specific ways. Despite receiving standard immunosuppression, rejection patients maintained heightened overall immune activity. The team observed an expansion of KIR-expressing effector memory CD8 T cell populations in these patients. KIR, or killer cell immunoglobulin-like receptors, are molecules classically associated with natural killer cells that tune their reactivity to self, but their expression on CD8 T cells marks a subset with distinctive effector properties. The rejection group also showed increased expression of IRF1, a transcription factor that sits downstream of interferon signaling and orchestrates inflammatory gene programs in CD8 T cells. In other words, the post-transplant immune landscape of rejecters retained an activated, interferon-driven character that immunosuppression failed to fully extinguish.

To move from descriptive biology toward clinical utility, the researchers searched for genes whose expression reliably distinguished rejecting from non-rejecting patients across multiple time points. They identified 15 robust acute rejection-associated genes that were consistently detected before and after transplantation, and then validated a subset of these genes in liver biopsy tissue from the patients. This cross-validation is important: it links the circulating blood signature to the actual immunological battleground inside the graft, supporting the idea that a peripheral blood test could serve as a proxy for processes occurring in the transplanted liver. A blood-based biomarker panel built on such genes could, in principle, flag high-risk patients before rejection becomes clinically manifest, allowing clinicians to intensify monitoring or tailor immunosuppressive regimens without resorting to repeated biopsies.

The implications reach beyond liver transplantation. Acute cellular rejection is fundamentally a problem of immune recognition and memory, and the Yonsei study demonstrates that the relevant information is encoded in the composition and activation state of circulating immune cells. The finding that pre-transplant immune states predispose recipients to rejection challenges the traditional view of rejection as a purely post-transplant event driven by donor-recipient mismatch alone. Instead, the recipient’s baseline immune configuration, shaped by their disease history, viral exposures, and inflammatory milieu, appears to set the stage for how the immune system will respond to the graft. This reframing aligns with a broader trend in transplant immunology toward precision medicine, in which immunological risk stratification replaces one-size-fits-all immunosuppression.

There are, of course, important caveats. The study involved 20 carefully matched patients, a sample size appropriate for discovery but too small to support immediate clinical deployment of a diagnostic test. The 15-gene signature and the cellular features identified will need validation in larger, independent, and ideally multi-center cohorts before they can inform treatment decisions. It also remains to be seen whether the signatures generalize across different donor types, immunosuppressive protocols, and causes of liver failure. Nonetheless, the methodological framework, integrating single-cell transcriptomics, T cell receptor repertoire tracking, regulatory network inference, and tissue validation, provides a template that other transplant programs can adopt to build the evidence base needed for clinical translation.

For patients awaiting a liver, the promise is tangible: a pre-operative blood draw that reveals whether their immune system is primed for conflict, and post-operative monitoring that catches rejection in its earliest molecular stages rather than after tissue damage has occurred. For the field of transplant immunology, the study adds a detailed cellular and molecular atlas of how rejection unfolds in the human circulation, from interferon-primed natural killer cells and interferon-signature monocytes to KIR-expressing effector memory CD8 T cells and IRF1-driven inflammatory programs. As single-cell sequencing becomes faster and cheaper, the vision of routine immune profiling before and after organ transplantation moves closer to reality, and with it the possibility of preventing rejection rather than merely treating it.

Subject of Research: Single-cell RNA sequencing and T cell receptor repertoire analysis of immune signatures associated with acute liver allograft rejection

Article Title: Integrative single-cell RNA-seq and TCR repertoire analysis reveals distinct immunological features of acute liver allograft rejection

Article References: Lee, S.-H., Kim, D.-G., Cho, Y., Min, E.-K., Lee, J. G., Kim, M. S., Park, S., Hwang, B., & Joo, D. J. (2026). Integrative single-cell RNA-seq and TCR repertoire analysis reveals distinct immunological features of acute liver allograft rejection. Genome Medicine. https://doi.org/10.1186/s13073-026-01753-4

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01753-4

Keywords: liver transplantation, acute rejection, single-cell RNA sequencing, T cell receptor repertoire, CD8 T cells, natural killer cells, monocytes, interferon signaling, IRF1, biomarkers, immunosuppression, Genome Medicine